TMFOX
73 Upper Paya Rd 06-01c, Bianco, Singapore, Central Region
Overview
We are aptly named because we are all about integrating technologies, management, marketing, and capitals into entrepreneurs’ fortune creation and producing the success of our client companies. TMFOX is a boutique investment bank for Hi-Tech and we dedicated to innovating our life better. Started from China Innovation heartland, Shenzhen since 2009 into Global reach, TMFOX has been in severing our client's growth strategy, capitals, product roadmap with holistic solutions and insights. TMFOX operates in SHENZHEN, DONGGUAN, GUANGZHOU, ZHONGSHAN, HUIZHOU (The great bay area of China) and has an international presence in great Vancouver, Seattle, Boston. TMFOX has advised 600+ global clients with over 1 billion USD funding and built over 10,000 entrepreneurs community with straight forward industrial focuses of health care, IoT, and smart manufacture. TMFOX also manages 30 million USD venture and angel fund.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Health Care
Investment portfolio
- Sonic Incytes
Participated · Seed · May 2020
Sonic Incytes Medical develops Velacur™, a handheld, point-of-care 3D liver health assessment solution that quantifies liver disease with technology similar to MRI elastography combined with 3D tissue sampling. Velacur is FDA-cleared, non-invasive, delivers results in about five minutes, and was launched in the U.S. market in early 2021. The device is intended to provide consistently accurate, real-time liver diagnostics in a physician’s office as an alternative to biopsy and MRI. Sonic Incytes positions the product as accessible and affordable to enable routine assessment and improved management of chronic liver disease. The company emphasizes reducing fatty liver disease and improving patient care through point-of-care ultrasound diagnostics. Founded in 2017 and headquartered in Vancouver, British Columbia, Sonic Incytes spun out of the University of British Columbia. Sonic Incytes Medical develops a portable, handheld point-of-care ultrasound solution for assessing and managing chronic liver disease, with a focus on fatty liver disease. The device uses technology similar to MRI elastography and quantifies liver disease using 3D tissue sampling to provide consistently accurate, real-time results. The company says the entire procedure takes about five minutes and offers a quick, safe, and comfortable alternative to biopsy and MRI. Sonic Incytes plans to enter the market at the end of 2020. Financially, it completed a seed financing round of over CDN$3.5 million, including a $1 million investment from Genome BC and over $2.5 million from institutional and angel investors. Founded in 2017 and headquartered in Vancouver, British Columbia, Sonic Incytes aims to commercialize its solution to improve diagnosis, treatment and management of liver disease.
Team
No current team members are available.